|Bid||170.60 x 1100|
|Ask||170.80 x 1400|
|Day's range||158.21 - 171.92|
|52-week range||30.98 - 189.26|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||N/A|
|Earnings date||05 May 2021 - 10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||175.58|
The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.
What happened Shares of Moderna (NASDAQ: MRNA) rose 6.8% on Friday, as analysts and investors grew more optimistic about the vaccine maker's growth prospects. So what Piper Sandler analyst Edward Tenthoff repeated his overweight rating on Moderna's stock and boosted his price forecast from $208 to $234 on Thursday.
Assistant Professor of Emergency Medicine at Baylor College of Medicine, Dr. Sara Andrabi, joined Yahoo Finance to break down her thoughts on the possibility of needing annual COVID-19 booster shots to.